share_log

Guggenheim Initiates Coverage On Myriad Genetics With Buy Rating, Announces Price Target of $23

Guggenheim Initiates Coverage On Myriad Genetics With Buy Rating, Announces Price Target of $23

古根海姆以买入评级启动对Myriad Genetics的报道,宣布目标股价为23美元
Benzinga ·  2023/12/14 06:36

Guggenheim analyst Subbu Nambi initiates coverage on Myriad Genetics (NASDAQ:MYGN) with a Buy rating and announces Price Target of $23.

古根海姆分析师Subbu Nambi以买入评级开始报道Myriad Genetics(纳斯达克股票代码:MYGN),并宣布目标股价为23美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发